Position in LLY
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$5,224,717
+$1,627,497 QoQ
Shares Held
4,356
+11.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
1.63%
of 13F equity value
Holder Rank
#1,674
of 4,605 holders
Holding Since
Sep 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Thrive Capital Management, LLC holds $24,319,388 across 7 Drug Manufacturers - General names. LLY ranks #3 (21.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
26,428 | $6,711,919 | |
| 2 | MRK |
Merck & Co., Inc.
|
42,844 | $5,505,454 | |
| 3 | LLY |
ELI LILLY & Co
This page
|
4,356 | $5,224,717 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
34,523 | $4,361,635 | |
| 5 | AMGN |
Amgen Inc
|
4,477 | $1,621,211 | |
| 6 | ABBV |
AbbVie Inc.
|
1,905 | $479,374 | |
| 7 | AZN |
Astrazeneca PLC
|
2,189 | $415,078 |
All Filings in LLY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,224,717 | 4,356 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $3,597,220 | 3,911 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $584,625 | 544 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $379,211 | 497 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $378,851 | 486 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $276,679 | 335 | Shares | Sole | 2025-04-30 | |
| 2024-09-30 | $446,513 | 504 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $442,730 | 489 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $378,088 | 486 | Shares | Sole | 2024-05-13 | |
| 2023-12-31 | $253,570 | 435 | Shares | Sole | 2024-01-29 | |
| 2023-09-30 | $233,114 | 434 | Shares | Sole | 2023-11-02 | |
| No filing history on record for this holder in this stock. | ||||||